Depression Clinical Trial
Official title:
Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive Disorder : A 13-week, Double-Blind, Placebo-Controlled, Cross-Over Trial
Verified date | February 2017 |
Source | Tufts Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary outcome of this study is to determine if predictors of response can select a
population of patients with MDD that is effectively treatable by augmentation with
ziprasidone.
Major depressive disorder (MDD) is a broad category, including many forms of depressive
illness, including those with only a single major depressive episode, those with episodic
recurrence with intervening well states, those with chronic depressive/anxious states
without intervening euthymia, and those with manic symptoms that do not meet threshold
definitions of full mania/hypomania.
In this heterogenous, large diagnostic definition, important groups of patients do not
appear to respond well to antidepressants, and, conversely, based on observational studies,
may respond well to neuroleptics. These predictors of response have begun to be identified
and may serve to better design studies of neuroleptics in depressive illnesses.
Among these predictors of response in MDD are clinical features that are more similar to
bipolar illness than unipolar depression. These include a family history of bipolar
disorder, antidepressant-induced mania, highly recurrent depressive episodes (>5), atypical
depression, early age of onset of depression (< age 20), failure to respond to
antidepressants, and antidepressant tolerance (initial response followed by later loss of
response).
The investigators propose to use these predictors to pick out patients that are more likely
to respond to Geodon for MDD. This will be the first RCT of these predictors of depressive
response applied to neuroleptics.
Status | Completed |
Enrollment | 49 |
Est. completion date | December 2011 |
Est. primary completion date | December 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Age 18-70 years. 2. If female, nonpregnant/nonlactating 3. If a sexually active female of reproductive potential, must be using adequate contraception (i.e., oral contraceptives, barrier protection, or prior tubal ligation) 4. Currently meets DSM-IV criteria for a major depressive episode, non-psychotic. 5. Having at least 3 of the following criteria listed for predictors of depressive response to neuroleptics: a family history of bipolar disorder, antidepressant-induced mania, highly recurrent depressive episodes (>5), atypical depression, early age of onset of depression (< age 20), failure to respond to antidepressants, and antidepressant tolerance (initial response followed by later loss of response). Inadequate response to antidepressants is identified as follows: having a score of =14 on the 17-item HAMD or a CGI-S score of = 3 after a retrospective confirmation of an adequate trial of a single antidepressant (defined as a = 6-week trial of acceptable therapeutic dose [= 40 mg of fluoxetine, paroxetine or citalopram, 20 mg of escitalopram, 60 mg of duloxetine, 37.5 mg of paroxetine CR, 150 mg of sertraline, 100 mg of fluvoxamine, 225 mg of venlafaxine XR, 30 mg of mirtazapine, 300 mg of bupropion, 75 mg of nortriptyline, 20 mg of protriptyline, 100 mg of amitriptyline or imipramine) Exclusion Criteria: 1. Bipolar depression 2. Sensitivity to or failure to respond to ziprasidone by history or ziprasidone use in previous 3 months 3. Active substance abuse or dependence in the previous 3 month 4. Psychotic disorders 5. Serious suicidality as evidenced by score of 3 or greater on suicide item of MADRS 6. Medically unstable as judged by study investigators 7. Lack of capacity to provide informed, written, consent to investigators 8. Previous diagnosed cardiac arrhythmias |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Tufts Medical Center | Duke University, University of South Carolina |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | MADRS Improvement Over 6 Weeks | Montgomery Asberg Depression scale improvement was assessed in two 6 week crossover periods. Minimum score on MADRS is 0, the maximum is 60. Higher scores represent a worse outcome, i.e., greater severity of depressive symptoms. Scores of about 20 and above are generally seen as consistent with being in a full major depressive episode. No subscales were used or combined. |
13 weeks (Two 6 week periods plus a one week washout) | |
Secondary | Predictors of Bipolarity to Define the Study Population | The specific bipolarity predictors in patients with MDD were assessed. | 13 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A |